

Wockhardt net dives 94% on US woes

OUR BUREAU

Mumbai, August 12

Drug-maker Wockhardt saw its net profit fall 94 per cent for the three months ended June 30, as a ban on a couple of its plants took a toll on revenue in the US.

The company's net profit stood at ₹20 crore in the June quarter compared with ₹324 crore in the corresponding period last year. Consolidated revenue stood at

₹991 crore, down 27 percent from ₹1,358 crore.

Earlier this year, Wockhardt had received regulatory observations from the US Food and Drug Administration on its Morton Grove unit in the US even as it was grappling with import bans on two Indian plants. Products made at its Chikalthana and Waluj plants had been banned by the FDA for not adhering to GMP (Good Manufactur-

ing Practices) norms. The decline in its US business was evident as the region contributed just 29 per cent of the company's total revenue in the June quarter against 53 per cent last year. Revenue from this region stood at ₹287 crore in the quarter, down over 60 per cent compared with ₹722 crore a year earlier.

Wockhardt's Europe business (including France) contributed

about 34 per cent to global revenue, the company said. Revenue from EU (excluding France) were at ₹297 crore in the quarter, marginally down in rupee terms.

India and other emerging markets, contributing about 36 per cent of the company's global revenue, saw a 16 per cent growth. Revenues from these markets stood at ₹361 crore compared with ₹310 crore in the year-ago period.

company